Efficacy and Tolerability for Allegra and Allegra-D

For U.S. Healthcare Professionals Only

For Consumers

Allegra^® (fexofenadine HCl) is a powerful, non-sedating antihistamine that delivers 24-hour relief from allergy symptoms including sneezing, runny nose, itchy nose or throat, and itchy, watery eyes. Day and night, Allegra^® provides relief from allergic rhinitis symptoms
for a full 24 hours.^‡

Zoom in for study design
and references.

The FDA-approved label for Allegra^® has no Warnings regarding driving or drowsiness.

*Among OTC branded antihistamines.
^†Starts working at hour one. Applies to first dose only.
^‡Refers to 24-hour Allegra^® Allergy for adults.
^§Among OTC adult allergy brands in the United States for the period of April 2011 through March 2012.

Allegra-D^®

Provides statistically significant relief in 1 hour, even in high pollen levels^4-6
Reduces swelling of nasal passages so patients can breathe more freely
Is non-sedating and has no Warnings about drowsiness or important
daily activities, such as driving or operating machinery

*Starts working at hour one. Applies to first dose only.
^†Symptoms include nasal congestion; sinus congestion and pressure; runny nose; sneezing; itchy, watery eyes; itchy nose or throat.
^‡Among branded antihistamines/decongestants.

Click for references.

Sneezing
Itchy, watery eyes
Runny nose
Itchy nose or throat

Zoom in for study design
and references.

Significant improvement in total symptom scores as early as day 1—maintained over 2 weeks

Unlike some other antihistamines, Allegra^® does not cross the blood-brain barrier³

No sedation⁴
No psychomotor or cognitive impairment⁴

*Among OTC children’s allergy brands in the United States for the period of April 2011 through March 2012.

Allegra^® Allergy

Allegra-D^® Allergy & Congestion

Children’s Allegra^® Allergy

Allegra^® Allergy

24 Hour

12 Hour

Allegra-D^® Allergy
& Congestion

24 Hour

12 Hour

Children’s Allegra^® Allergy

Oral Suspension

Orally Disintegrating Tablets

Tablets

References: 1.The Nasal Allergies Market: US Core Therapeutic Report, National Health and Wellness Survey 2009. Princeton, NJ: Consumer Health Sciences A Kantar Health Company: 2009. 2. Shedden A. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis: findings from a large online survey. Treat Respir Med. 2005;4(6):439-446. 3. IMS National Disease and Therapeutic Index: Diagnosis/April 2011-March 2012. 4. Berkowitz RB, Woodworth GG, Lutz C, et al. Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit. Ann Allergy Asthma Immunol. 2002;89(1):38-45. 5. Berkowitz RB, McCafferty F, Lutz C, et al. Fexofenadine HCl 60 mg/pseudoephedrine HCl 120 mg has a 60-minute onset of action in the treatment of seasonal allergic rhinitis symptoms, as assessed in an allergen exposure unit. Allergy Asthma Proc. 2004;25(5): 335-343. 6. American Academy of Allergy Asthma & Immunology (AAAAI). NAB: Reading the charts. AAAAI Web site. http://www.aaaai.org/global/nab-pollen-counts/reading-the-charts.aspx. Accessed June 25, 2012.